Previous 10 | Next 10 |
RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief C...
RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced the company has awarded an unrest...
9 Meters Biopharma (NASDAQ:NMTR): Q3 GAAP EPS of -$0.05. Cash and cash equivalents of $53.6M Topline results from Phase 2 VIBRANT study with vurolenatide for SBS expected in Q1 2022. Press Release For further details see: 9 Meters Biopharma reports Q3 results
- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 - - Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 - - Appointed Samantha Ventimiglia of Vertex to the...
Collaboration builds upon previous positive preclinical data warranting further investigation of NM-102, a potential novel therapy to enhance immune checkpoint inhibitor effect IND-enabling pathway for NM-102 underway with indication selection anticipated in 2022 Composition of ma...
In-Person Dates: November 16 th -17 th Virtual Dates: November 18 th -19 th RALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by stud...
- Vurolenatide's half-life is consistent with twice-monthly dosing - - Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end - RALEIGH, NC / ACCESSWIRE / October 26, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company p...
RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today that the company will deliver a poster presentatio...
3 Top Penny Stocks For Your Mid-October Watchlist Blue chips and penny stocks are in highly volatile waters right now. With the Dow Jones Industrial Average shedding around 200 points on Wednesday, there are several things that all investors should be watching right now. For one, we are...
Analysts See Big Upside In These Penny Stocks Whether you’re looking for penny stocks to buy now or ones to add to a watch list, there’s a process involved in finding the best. Of course, a lot will depend on your strategy and outlook on the market. But there are a few bas...
News, Short Squeeze, Breakout and More Instantly...
9 Meters Biopharma Inc. Company Name:
NMTR Stock Symbol:
NASDAQ Market:
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President ...
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2...
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the r...